NorthWest Biotherapeutics Inc (NWBO)

[improving]

Gary, Fusion Pharmaceuticals (clinical stage phase 2 - prostrate cancer) was acquired by Merck in 2024 for $2.4 B (2 billion upfront):

Fusion Pharmaceuticals, March 2024, $2.4B: AstraZeneca acquired Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in next-generation radioconjugates (RCs), for $2.4 billion. This acquisition will help enhance AstraZeneca’s oncology portfolio by adding Fusion’s innovative RC pipeline, notably FPI-2265, a potential metastatic castration-resistant prostate cancer (mCRPC) treatment. The acquisition was completed in June 2024 Source-https://intellizence.com/insights/merger-and-acquisition/mergers-acquisitions-by-top-biotechnology-companies-2024/

It seems AZ was more interested in "potential value" than Fusion's current sales and earnings. "Together with Fusion, we have an "opportunity" to accelerate the development of FPI-2265 as a "potential new treatment" for prostate cancer" PR Newswire. (emphasis added " ".)

Now NWBO has completed successful phase three trials, and most here feel the MHRA would have denied approval of its cancer treating platform by now if it were unsatisfied with the trial results. It seems to me this company, given the likelihood of approval, and with approval the likelihood of gaining approval for treating many additional solid tumor cancers, and given its safety profile, is grossly manipulated in terms of share price and market cap. We'll see what develops.
Regards.
_____________________________________________________________

We're all entitled to our opinions, but you're telling me nothing about sales of DCVax-L or the earnings the company should be seeing

.